Sponsor or institution
Clinical trials and research at GBG Forschungs GmbH
As of November 12, 2026, Find a Trial lists 4 clinical trials run by GBG Forschungs GmbH that are recruiting, at sites in 7 countries (most in Germany (3), Spain (2), Italy (1)). By phase: Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 7Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Combining capivasertib with fulvestrant for high-risk lobular breast cancer | Phase 2 | Augsburg and 24 other locations | Recruiting | Sep 23, 2024 |
| Combining Elacestrant with Olaparib for Advanced Breast Cancer Treatment | Phase 2 | Stuttgart, Baden-Wurttemberg and 35 other locations | Recruiting | Jan 11, 2024 |
| Long-term follow-up for breast cancer patients from GBG trials | — | Innsbruck, Triol and 22 other locations | Recruiting | Feb 22, 2023 |
| Neoadjuvant therapy with or without Inavolisib for early HER2-positive breast cancer | Phase 2 | Essen, North Rhine-Westphalia and 61 other locations | Recruiting | Mar 31, 2022 |
All recruiting trials (4)
-
Combining capivasertib with fulvestrant for high-risk lobular breast cancer
This study is testing if adding capivasertib to fulvestrant can help postmenopausal women with high-risk lobular breast cancer more than using fulvestrant alone.
-
Combining Elacestrant with Olaparib for Advanced Breast Cancer Treatment
This study is testing if adding elacestrant to olaparib can help people with advanced breast cancer who have specific genetic mutations live longer without their cancer getting worse.
-
Long-term follow-up for breast cancer patients from GBG trials
This study is looking to see how well different treatments work for early breast cancer patients over the long term and how they affect things like survival, side effects, and quality of life.
-
Neoadjuvant therapy with or without Inavolisib for early HER2-positive breast cancer
This study is testing if adding a new drug called Inavolisib to standard treatment can help women with early HER2-positive breast cancer respond better before surgery.
Quick answers
How many clinical trials run by GBG Forschungs GmbH are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 7 countries. The most sites are in Germany (3 trials), Spain (2 trials), Italy (1 trial), Poland (1 trial), Romania (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.